<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00068523</url>
  </required_header>
  <id_info>
    <org_study_id>ICC7Y02</org_study_id>
    <nct_id>NCT00068523</nct_id>
  </id_info>
  <brief_title>Ultraviolet-B Light Therapy and Allogeneic Stem Cell Transplantation in Treating Patients With Hematologic Malignancies</brief_title>
  <official_title>Immunomodulation by Ultraviolet B-Irradiation (UVB) to Facilitate Allogeneic Stem Cell Transplantation for Treatment of Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Case Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Case Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were&#xD;
      destroyed by chemotherapy. Sometimes the transplanted cells from a donor are rejected by the&#xD;
      body's normal cells. Ultraviolet-B light therapy given before and after allogeneic stem cell&#xD;
      transplantation may help prevent this from happening.&#xD;
&#xD;
      PURPOSE: Clinical trial to study the effectiveness of combining ultraviolet-B light therapy&#xD;
      with allogeneic stem cell transplantation in treating patients who have hematologic&#xD;
      malignancies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the safety of ultraviolet-B light therapy and allogeneic peripheral blood stem&#xD;
           cell transplantation in patients with hematologic malignancies by demonstrating 100-day&#xD;
           mortality no greater than 15% and 1-year mortality no greater than 40%.&#xD;
&#xD;
        -  Determine the frequency of treatment-related toxicity leading to death and frequency of&#xD;
           disease relapse resulting in death in patients treated with this regimen.&#xD;
&#xD;
        -  Determine the incidence and severity of acute and chronic graft-versus-host disease in&#xD;
           patients treated with this regimen.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the rates of donor allogeneic hematologic engraftment in patients treated with&#xD;
           this regimen.&#xD;
&#xD;
        -  Determine the rate and quality of immune reconstitution in the peripheral blood and the&#xD;
           composition of immune cells in the skin before and after transplantation in these&#xD;
           patients.&#xD;
&#xD;
        -  Determine the event-free and overall survival of patients treated with this regimen.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
        -  Preparative regimen: Patients receive fludarabine IV over 30 minutes on days -8 to -4&#xD;
           and cyclophosphamide IV over 1 hour on days -3 to -2. Patients also receive&#xD;
           anti-thymocyte globulin IV over 4 hours on days -2 to -1. Patients undergo ultraviolet-B&#xD;
           (UVB) light therapy every other day between days -10 and -2 for a total of 3 days.&#xD;
&#xD;
        -  Allogeneic peripheral blood stem cell (PBSC) transplantation: Patients undergo PBSC&#xD;
           transplantation on day 0.&#xD;
&#xD;
        -  Graft-versus-host disease prophylaxis: Patients receive oral cyclosporine on days -1 to&#xD;
           100 and methylprednisolone (oral or IV) on days 5-15.&#xD;
&#xD;
        -  Posttransplantation UVB light therapy: Following PBSC transplantation, patients undergo&#xD;
           UVB light therapy twice weekly on week 1 (at least 1 day apart) and three times weekly&#xD;
           on weeks 2-4.&#xD;
&#xD;
      Donor lymphocyte infusion is performed per institutional guidelines for patients in whom&#xD;
      emerging donor chimerism post allogeneic PBSC transplantation is not progressing&#xD;
      (consistently below 50% during first 3 months), for whom donor chimerism is receding (to&#xD;
      below 25%) despite cessation of cyclosporine, or who relapse within 24 months after&#xD;
      allografting.&#xD;
&#xD;
      Patients are followed at least monthly for 3 months and then at 6, 12, 18, and 24 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 23-36 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2003</start_date>
  <primary_completion_date type="Actual">March 2004</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Study the effectiveness of combining ultraviolet-B light therapy with allogeneic stem cell transplantation in treating patients who have hematologic malignancies.</measure>
    <time_frame>Patients are followed at least monthly for 3 months and then at 6, 12, 18, and 24 months.</time_frame>
  </primary_outcome>
  <enrollment type="Actual">10</enrollment>
  <condition>Chronic Myeloproliferative Disorders</condition>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Myelodysplastic/Myeloproliferative Diseases</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>anti-thymocyte globulin</intervention_name>
    <description>anti-thymocyte globulin IV over 4 hours on days -2 to -1</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>cyclophosphamide IV over 1 hour on days -3 to -2</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclosporine</intervention_name>
    <description>oral cyclosporine on days -1 to 100</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine phosphate</intervention_name>
    <description>fludarabine IV over 30 minutes on days -8 to -4</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methylprednisolone</intervention_name>
    <description>methylprednisolone (oral or IV) on days 5-15</description>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>UV light therapy</intervention_name>
    <description>Patients undergo ultraviolet-B (UVB) light therapy every other day between days -10 and -2 for a total of 3 days. Posttransplantation UVB light therapy: Following PBSC transplantation, patients undergo UVB light therapy twice weekly on week 1 (at least 1 day apart) and three times weekly on weeks 2-4.</description>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>allogeneic bone marrow transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
    <description>Allogeneic peripheral blood stem cell (PBSC) transplantation: Patients undergo PBSC transplantation on day 0.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed diagnosis of any of the following hematologic malignancies:&#xD;
&#xD;
               -  Acute myeloid leukemia (AML) meeting any of the following criteria:&#xD;
&#xD;
                    -  First complete remission with high-risk karyotype&#xD;
&#xD;
                         -  Translocations t(15;17) allowed only if failed first-line induction&#xD;
                            therapy OR molecular evidence of persistent disease exists&#xD;
&#xD;
                         -  Translocations t(8;21) and inv(16) allowed only if failed first-line&#xD;
                            induction therapy&#xD;
&#xD;
                    -  Second or subsequent complete remission&#xD;
&#xD;
                    -  Minimal residual disease*&#xD;
&#xD;
               -  Acute lymphoblastic leukemia meeting any of the following criteria:&#xD;
&#xD;
                    -  Failed induction therapy and has minimal residual disease* by salvage&#xD;
                       therapy&#xD;
&#xD;
                    -  First complete remission with high-risk karyotype (e.g., t[4;11] or t[9;22])&#xD;
&#xD;
                    -  Relapsed disease allowed provided a second or subsequent complete remission&#xD;
                       or minimal residual disease* is achieved&#xD;
&#xD;
               -  Chronic myelogenous leukemia meeting any of the following criteria:&#xD;
&#xD;
                    -  Persistent or relapsed disease after 1 year of imatinib mesylate therapy&#xD;
&#xD;
                    -  Accelerated phase or blast crisis&#xD;
&#xD;
                         -  Blast crisis allowed after reinduction chemotherapy places disease in&#xD;
                            chronic phase&#xD;
&#xD;
               -  Myelodysplastic syndromes meeting any of the following criteria:&#xD;
&#xD;
                    -  Refractory to medical management&#xD;
&#xD;
                    -  Cytogenetic abnormalities predictive of transformation into acute leukemia,&#xD;
                       including 5q-, 7q-, monosomy 7 and trisomy 8, or evidence of evolution to&#xD;
                       AML (e.g., refractory anemia with excess blasts (RAEB) or RAEB in&#xD;
                       transformation)&#xD;
&#xD;
               -  Non-Hodgkin's lymphoma or Hodgkin's lymphoma meeting any of the following&#xD;
                  criteria:&#xD;
&#xD;
                    -  Beyond first complete remission or failed primary induction therapy and&#xD;
                       demonstrated sensitivity to therapy during the 6 months before&#xD;
                       transplantation&#xD;
&#xD;
                    -  Recurrent disease after autologous stem cell transplantation&#xD;
&#xD;
                         -  Must be at least 3 months posttransplantation&#xD;
&#xD;
                    -  Cyclin D1+ mantle cell lymphoma allowed after induction therapy and in first&#xD;
                       remission&#xD;
&#xD;
               -  Multiple myeloma meeting either of the following criteria:&#xD;
&#xD;
                    -  Refractory or relapsed disease&#xD;
&#xD;
                    -  Residual disease after autologous transplantation&#xD;
&#xD;
               -  Chronic lymphocytic leukemia (CLL) meeting all of the following criteria:&#xD;
&#xD;
                    -  Peripheral blood absolute lymphocyte count greater than 5,000/mm^3&#xD;
&#xD;
                    -  Small to moderate size lymphocytes and less than 55% pro-lymphocytes,&#xD;
                       atypical lymphocytes, or lymphoblasts morphologically&#xD;
&#xD;
                    -  B-cell or T-cell&#xD;
&#xD;
               -  Myeloproliferative disorders, including myelofibrosis&#xD;
&#xD;
                    -  Philadelphia negative&#xD;
&#xD;
          -  Availability of a HLA-A, B, and DR identical family donor OR HLA-A, B, and DR&#xD;
             genetically matched unrelated donor&#xD;
&#xD;
          -  Must meet 1 of the following criteria:&#xD;
&#xD;
               -  At least 55 years of age at time of transplantation&#xD;
&#xD;
               -  Received extensive prior therapy (i.e., more than 1 year of alkylator therapy or&#xD;
                  more than 2 different prior salvage regimens) or stem cell transplantation with&#xD;
                  myeloablative conditioning (either autologous or allogeneic)&#xD;
&#xD;
               -  Presenting with comorbid condition (e.g., abnormal cardiac, pulmonary, or renal&#xD;
                  function and/or prior life-threatening infection) that precludes eligibility for&#xD;
                  enrollment in allogeneic transplantation protocols with full ablation&#xD;
                  conditioning&#xD;
&#xD;
          -  No active CNS disease NOTE: *Defined as having no circulating blasts, absolute&#xD;
             neutrophil count greater than 1,000/mm3 and less than 10% blasts in bone marrow at&#xD;
             least 3 weeks after last systemic chemotherapy&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Over 18&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 3 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin no greater than 2.0 mg/dL&#xD;
&#xD;
          -  ALT/AST no greater than 4 times normal&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Creatinine less than 2.0 mg/dL OR&#xD;
&#xD;
          -  Creatinine clearance at least 50 mL/min&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Normal cardiac function by echocardiogram or radionuclide scan&#xD;
&#xD;
          -  Shortening fraction or ejection fraction at least 40% of normal&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  DLCO at least 60%&#xD;
&#xD;
          -  FEV_1 greater than 50% of predicted&#xD;
&#xD;
          -  Pulse oximetry greater than 85%&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No uncontrolled active infection&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 2 weeks since prior biologic response modifiers, signal transduction&#xD;
             inhibitors, or monoclonal antibodies&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior systemic conventional chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Recovered from prior therapy&#xD;
&#xD;
          -  No concurrent sun block/sunscreen or any cosmetic that may act as a sunscreen (e.g.,&#xD;
             lotion with SPF) on the days of scheduled ultraviolet-B light therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Omer N. Koc, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>September 10, 2003</study_first_submitted>
  <study_first_submitted_qc>September 10, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 11, 2003</study_first_posted>
  <last_update_submitted>July 23, 2020</last_update_submitted>
  <last_update_submitted_qc>July 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2020</last_update_posted>
  <responsible_party>
    <name_title>Omer N. Koc, MD</name_title>
    <organization>Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center</organization>
  </responsible_party>
  <keyword>refractory multiple myeloma</keyword>
  <keyword>accelerated phase chronic myelogenous leukemia</keyword>
  <keyword>adult acute lymphoblastic leukemia in remission</keyword>
  <keyword>adult acute myeloid leukemia in remission</keyword>
  <keyword>blastic phase chronic myelogenous leukemia</keyword>
  <keyword>recurrent adult acute lymphoblastic leukemia</keyword>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>refractory chronic lymphocytic leukemia</keyword>
  <keyword>relapsing chronic myelogenous leukemia</keyword>
  <keyword>de novo myelodysplastic syndromes</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>recurrent adult Burkitt lymphoma</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent adult lymphoblastic lymphoma</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>refractory anemia with excess blasts in transformation</keyword>
  <keyword>refractory anemia with excess blasts</keyword>
  <keyword>secondary myelodysplastic syndromes</keyword>
  <keyword>Philadelphia chromosome negative chronic myelogenous leukemia</keyword>
  <keyword>chronic idiopathic myelofibrosis</keyword>
  <keyword>B-cell chronic lymphocytic leukemia</keyword>
  <keyword>T-cell large granular lymphocyte leukemia</keyword>
  <keyword>chronic phase chronic myelogenous leukemia</keyword>
  <keyword>recurrent adult Hodgkin lymphoma</keyword>
  <keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
  <keyword>stage III chronic lymphocytic leukemia</keyword>
  <keyword>stage IV chronic lymphocytic leukemia</keyword>
  <keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
  <keyword>secondary acute myeloid leukemia</keyword>
  <keyword>atypical chronic myeloid leukemia</keyword>
  <keyword>myelodysplastic/myeloproliferative disease, unclassifiable</keyword>
  <keyword>recurrent marginal zone lymphoma</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <keyword>adult acute myeloid leukemia with t(8;21)(q22;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with inv(16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>adult acute myeloid leukemia with t(15;17)(q22;q12)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

